-
Overall Survival with First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial
Sonke, G. S., Wortelboer, N., van Ommen-Nijhof, A., Konings, I. R., van der Noort, V., van den Pol, E., Guerrero Páez, C., Bakker, S. D., Hovenga, S., Imholz, A. L. T., Kamm, Y. J. L., van Leeuwen, L., Luykx-de Bakker, S. A., Mandigers, C. M. P. W., van Riel, J. M. G. H., Tol, J., van de Wouw, A. J., Wilting, S. M., van Leeuwen-Stok, A. E. & Jager, A. & 1 others, , 16 Apr 2026, In: JAMA oncology. 12, 4, p. 375-383 9 p.Research output: Contribution to Journal › Article › Academic
-
CDK4/6 inhibitors in advanced breast cancer Improving treatment strategies and patient outcomes
Wortelboer, N., 2026, 321 p.Research output: PhD Thesis › PhD-Thesis - Research and graduation internal
-
Cognitive function during endocrine treatment with or without cyclin-dependent kinase 4/6 inhibitors for advanced breast cancer
Luijendijk, M. J., Lee Meeuw Kjoe, P. R., Wortelboer, N., van Ommen-Nijhof, A., van Leeuwen-Stok, A. E., Agelink van Rentergem, J. A., Vermeulen, I. E., Konings, I. R., Jager, A., Sonke, G. S., van der Wall, E. & Schagen, S. B., 15 Dec 2025, In: Cancer. 131, 24, p. 1-12 12 p., e70212.Research output: Contribution to Journal › Article › Academic › peer-review
- All publications
